Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.50    0.50 (0.68%)
Bid:
72.00
Ask:
75.00
Spread: 3.00 (4.167%)
Market Cap: £344.38m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Change

7 Jul 2006 16:07

Readybuy PLC07 July 2006 Readybuy plc Board appointments Readybuy plc (the "Company") announces the appointment of Daron Lee asnon-executive chairman and Professor Alastair Smith as a non-executive directorof the Company. The Company also announces the resignations of Colin Davies andKeith Salisbury with immediate effect. Daron Ross Lee (aged 39), commenced his career with stockbrokers Ashworth Sons &Barratt in 1987 before pursuing other opportunities within the family business.He then returned to stockbroking with WH Ireland Limited before establishingProquote Limited ("Proquote"), a business engaged in the provision of on-linestockmarket data and company information. Proquote was sold in February 2003 tothe London Stock Exchange plc and Daron remained with Proquote as its managingdirector until the end of 2004. Since then Daron has pursued a number ofpersonal business interests. Daron Lee is interested in 15,000,000 ordinary shares of 0.1p each in thecapital of the Company ("Ordinary Shares"), representing 12.06 per cent. of theissued ordinary share capital of the Company, and warrants to subscribe for7,500,000 Ordinary Shares. Professor David Alastair Maclaughlin Smith (aged 39), is a director of AvactaLimited, Avacta Analytical Limited and TT123 Limited. During the past fiveyears he has also been a director of Hebden Lodge Hotel Company Limited. He hasa degree and PhD in Physics from Manchester University and, after working in theUS for a period, took up a position at Leeds University in 1995. Alastair hasspent the last 10 years developing new biophysical technologies and applyingthem to problems in structural molecular biology. At the age of 38 he wasawarded a Chair of Molecular Biophysics for this work and he also holds theDirectorship of the Institute of Molecular Biophysics at Leeds University. There are no other disclosures required under Schedule Two (g) of the AIM rules. For further information please contact: Daron Lee, Readybuy plc Tel: 07802 88 89 11David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20217:00 amRNSAffiDX Lateral Flow Test Detects Delta Variant
28th Jun 202112:13 pmRNSResult of AGM
21st Jun 20212:05 pmRNSSecond Price Monitoring Extn
21st Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSAffiDX Lateral Flow Test Distribution Agreement
15th Jun 20218:00 amRNSIssue of Equity and Total Voting Rights
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:07 amRNSRegistration of AffiDX Lateral Flow Test in EU
9th Jun 20219:08 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSMHRA Confirms Registration of Lateral Flow Test
1st Jun 20217:00 amRNSUpdate on Lateral Flow Test Regulatory Submissions
28th May 20217:00 amRNSResponse to speculation
25th May 202110:00 amRNSPosting of Annual Report and Notice of AGM
10th May 202110:36 amRNSAffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
6th May 20217:00 amRNSChange of Nominated Adviser
30th Apr 202112:37 pmRNSIssue of Equity
28th Apr 20215:18 pmRNSIssue of Equity
28th Apr 20214:41 pmRNSSecond Price Monitoring Extn
28th Apr 20214:36 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSFinal Results
20th Apr 202111:05 amRNSSecond Price Monitoring Extn
20th Apr 202111:00 amRNSPrice Monitoring Extension
20th Apr 20217:00 amRNSClinical validation of AffiDX Lateral Flow Test
15th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:00 amRNSNotice of Results and Investor Presentation
12th Apr 20211:30 pmRNSIssue of Equity
6th Apr 20217:00 amRNSDistribution Agreement with ABCAM plc
25th Mar 20213:01 pmRNSDirectorate Change
16th Mar 20215:08 pmRNSIssue of Equity
15th Mar 20215:22 pmRNSIssue of Equity
9th Mar 20217:00 amRNSDiagnostic Licensing Deal with Biokit
8th Mar 20217:00 amRNSRapid Antigen Test Detects SARS-CoV-2 Variants
3rd Mar 20215:14 pmRNSElectronic Communications with Shareholders
24th Feb 20217:00 amRNSBusiness Update
22nd Feb 20217:00 amRNSRe: Press Speculation
18th Feb 20217:00 amRNSPhase I CTA for AVA6000 Approved by MHRA
16th Feb 20219:05 amRNSSecond Price Monitoring Extn
16th Feb 20219:00 amRNSPrice Monitoring Extension
16th Feb 20217:00 amRNSResults of Initial Evaluation of SARS-CoV-2 LFT
8th Feb 20217:00 amRNSCommercial Partnership with Mologic
2nd Feb 20218:30 amRNSIssue of Equity
1st Feb 20217:00 amRNSAffyXell $7.3 Million Series A Financing
29th Jan 202111:00 amRNSIssue of Equity
28th Jan 20217:00 amRNSCollaboration Agreement with Bruker
7th Jan 20217:00 amRNSLicense Agreement with POINT Biopharma Inc.
5th Jan 202111:05 amRNSSecond Price Monitoring Extn
5th Jan 202111:00 amRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSSubmission of CTA for AVA6000 Pro-doxorubixin

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.